High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Daratumumab is a CD38‐targeted human monoclonal antibody with direct anti‐myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T‐cell expansion and reduction of immune‐suppressive populations, sug...

Full description

Saved in:
Bibliographic Details
Published in:Cytometry A
Main Authors: Adams, Homer C., Stevenaert, Frederik, Krejcik, Jakub, Van der Borght, Koen, Smets, Tina, Bald, Jaime, Abraham, Yann, Ceulemans, Hugo, Chiu, Christopher, Vanhoof, Greet, Usmani, Saad Z., Plesner, Torben, Lonial, Sagar, Nijhof, Inger, Lokhorst, Henk M., Mutis, Tuna, van de Donk, Niels W.C.J., Sasser, Amy Kate, Casneuf, Tineke
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Inc. 2018
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590645/
https://ncbi.nlm.nih.gov/pubmed/30536810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cyto.a.23693
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items